Abstract
The purpose of this study was to characterize the kinetics and voltage-dependence of the block ofN-methyl-d-aspartate (NMDA)-induced currents in primary cultures of rat cortical neurons by the neuroprotective, low-affinity, NMDA antagonist ARL 15896AR, using whole-cell voltage-clamp techniques. ARL 15896AR caused rapid and reversible inhibition of NMDA (50 μM)-evoked currents from neurons held at −60 mV, with an IC50 of 9.8 μM. The EC50 for NMDA was not significantly affected by 10 μM ARL 15896AR (P > .05), consistent with a noncompetitive mechanism of block. ARL 15896AR antagonism was use-dependent, because application of the drug 60 sec before NMDA did not attenuate the initial NMDA-evoked current, although the block developed rapidly thereafter. Once bound, ARL 15896AR remained trapped upon removal of NMDA until subsequent NMDA re-exposure, whereupon currents recovered rapidly. The forward and reverse binding rate constants were estimated to be 2.406 × 104 M−1 sec−1 and 0.722 sec−1, respectively. Antagonism was strongly voltage-dependent; the K D values at 0 and −60 mV were 60 and 11 μM, respectively. Additionally, there was a component of the block by ARL 15896AR that was voltage-insensitive. This component of the block did not act at the ligand binding site, because it was not influenced by NMDA concentration, or at the polyamine site, because it was not affected by spermine. However, there was an interaction of ARL 15896AR with the glycine regulatory site. In contrast to many uncompetitive NMDA antagonists, like MK-801, ARL 15896AR exhibited rapid kinetics. This property may result in a large margin of safety while maintaining the efficacy associated with use-dependent NMDA antagonists, making this compound an excellent candidate for clinical trials.
Footnotes
-
Send reprint requests to: Geoff Mealing, Institute for Biological Sciences, National Research Council of Canada, Building M54, Montreal Rd., Ottawa, Ontario, Canada, K1A 0R6.
-
↵1 This work was supported by the Canada/Astra Fight Stroke Program, funded by the National Research Council of Canada and Astra Pharma Inc. (Mississauga, Ontario, Canada).
- Abbreviations:
- ADCI
- 5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine
- ARL 15896AR
- (S)-α-phenyl-2-pyridineethanamine dihydrochloride
- HEPES
- N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)
- MEM
- minimal essential medium
- NMDA
- N-methyl-d-aspartic acid
- PCP
- phencyclidine
- Received September 17, 1996.
- Accepted December 9, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|